ALLMedicine™ Cystinuria Center
Research & Reviews 331 results
https://doi.org/10.1016/j.urology.2020.12.025
Urology Daga S, Palit V et. al.
Jan 9th, 2021 - Cystinuria is the most common cause of inherited stone disease and is caused by the failure of absorption of filtered dibasic amino acids including cystine in the proximal tubules. It is associated with a very high recurrence rate in affected pati...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758038
Renal Failure; Tkaczyk M, Gadomska-Prokop K et. al.
Dec 22nd, 2020 - Cystinuria is an inherited disorder that results in increased excretion of cystine in the urine. It accounts for about 1-2% of pediatric kidney stones. In this study, we sought to identify the clinical characteristics of patients with cystinuria i...
https://doi.org/10.1007/s00345-020-03509-0
World Journal of Urology; Warren H, Poon D et. al.
Nov 10th, 2020 - Cystine stones are widely considered hard and difficult to treat. Hounsfield Units (HU) are used in other stone types to estimate 'hardness' and treatments based on that finding. Our objective was to report mean HU of cystine stones in vivo in a l...
https://doi.org/10.1016/j.kint.2020.06.035
Kidney International; Servais A, Thomas K et. al.
Sep 12th, 2020 - Cystinuria (OMIM 220100) is an autosomal recessive hereditary disorder in which high urinary cystine excretion leads to the formation of cystine stones because of the low solubility of cystine at normal urinary pH. We developed clinical practice r...
https://doi.org/10.1016/j.urology.2020.07.002
Urology Nelson CP, Kurtz MP et. al.
Jul 19th, 2020 - This is a case of an 8-year-old boy with a chief complaint of left-lower-quadrate abdominal pain for 3 days. Examination revealed swollen left hemi-scrotum and scrotal ultrasound showed a para-testicular cystic mass, which was later proven to be a...
Guidelines 1 results
http://ir.retrophin.com/news-releases/news-release-details/retrophin-announces-fda-approval-thiolar-ec-tiopronin-100mg-and
Jun 27th, 2019 - Retrophin, Inc. (NASDAQ: RTRX) today announced that the U.S. Food and Drug Administration (FDA) has approved 100 mg and 300 mg tablets of THIOLA® EC (tiopronin), a new enteric-coated formulation of THIOLA® (tiopronin), to be used for the treatmen...
Drugs 21 results see all →
Clinicaltrials.gov 367 results
https://doi.org/10.1016/j.urology.2020.12.025
Urology Daga S, Palit V et. al.
Jan 9th, 2021 - Cystinuria is the most common cause of inherited stone disease and is caused by the failure of absorption of filtered dibasic amino acids including cystine in the proximal tubules. It is associated with a very high recurrence rate in affected pati...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758038
Renal Failure; Tkaczyk M, Gadomska-Prokop K et. al.
Dec 22nd, 2020 - Cystinuria is an inherited disorder that results in increased excretion of cystine in the urine. It accounts for about 1-2% of pediatric kidney stones. In this study, we sought to identify the clinical characteristics of patients with cystinuria i...
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f658b20a-269f-4e78-a79b-a56a5ed8dc1b
Dec 3rd, 2020 - Penicillamine capsules are indicated in the treatment of Wilson's disease, cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy. Available evidence suggests th...
https://doi.org/10.1007/s00345-020-03509-0
World Journal of Urology; Warren H, Poon D et. al.
Nov 10th, 2020 - Cystine stones are widely considered hard and difficult to treat. Hounsfield Units (HU) are used in other stone types to estimate 'hardness' and treatments based on that finding. Our objective was to report mean HU of cystine stones in vivo in a l...
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4af8b0be-06ad-481f-9cff-61601da8fdd1
Sep 30th, 2020 - Penicillamine Capsules are indicated in the treatment of Wilson's disease, cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy. Available evidence suggests th...
News 7 results
https://www.medscape.com/viewarticle/915140
Jul 1st, 2019 - The US Food and Drug Administration (FDA) has approved an enteric-coated delayed-release formulation of tiopronin (Thiola EC, Retrophin) for treatment of cystinuria, a rare inherited disorder that causes an increase in cystine levels in the urine,...
http://ir.retrophin.com/news-releases/news-release-details/retrophin-announces-fda-approval-thiolar-ec-tiopronin-100mg-and
Jun 27th, 2019 - Retrophin, Inc. (NASDAQ: RTRX) today announced that the U.S. Food and Drug Administration (FDA) has approved 100 mg and 300 mg tablets of THIOLA® EC (tiopronin), a new enteric-coated formulation of THIOLA® (tiopronin), to be used for the treatmen...
https://www.medscape.com/viewarticle/551277_1
Feb 13th, 2007 - Introduction Symptomatic thalamic lesions are more frequently related to stroke, usually causing contralateral sensory symptoms, and less often to contralateral movement disorders. Thalamic lesions leading to movement disorders have been reported ...
https://www.medscape.com/viewarticle/551277
Feb 13th, 2007 - Introduction Symptomatic thalamic lesions are more frequently related to stroke, usually causing contralateral sensory symptoms, and less often to contralateral movement disorders. Thalamic lesions leading to movement disorders have been reported ...